ACS Global, Inc. has signed an agreement with Protein Genomics, Inc, to develop novel cellular therapies for the wound healing, regenerative and cellular therapy markets. Both the entities are based in the US. Under this agreement, ACS Global will contribute certain intellectual property, know how and trade secrets including clinically prepared adipose derived stem cells using its proprietary tissue processing and its patented stromal cell culture media. PGen will contribute certain know how and trade secrets including its patented, Elastatropin human based protein. ACS Global and PGen will initially focus their ongoing efforts towards creating applications for injuries and conditions that are difficult to treat, such as chronic, acute and traumatic wounds.